The latest Wegovy news and what it actually means for UK patients

The 7.2 mg pen approval: why a higher dose matters

For most of its time on the UK market, Wegovy's maximum maintenance dose was 2.4 mg weekly. That changed on 12 January 2026 when the MHRA authorised 7.2 mg as a maintenance dose, initially supplied as three 2.4 mg pens used in a single week. Three months later, on 14 April 2026, the MHRA approved a purpose-built single-dose 7.2 mg pen with an auto-dosing mechanism, a built-in covered needle, and a lock that activates after use, meaning one weekly injection at the higher strength.

The clinical rationale is straightforward: higher doses have produced greater weight loss in trials. At 7.2 mg, trial data reported average weight reduction of around 20.7 % over 72 weeks, a figure that starts to approach the results seen with tirzepatide at its maintenance doses in head-to-head evidence. The 7.2 mg licence applies to adults with a BMI of 30 or above; it does not extend to the lower BMI cardiovascular indication. The starting dose remains 0.25 mg, titrated by the prescriber roughly every four weeks.

A question our prescribers hear most weeks is whether someone already on 2.4 mg can simply step up. The honest answer is that it depends on individual clinical factors, tolerability, how the current dose is working, and the prescriber's assessment. There is no self-titration here. If you want to stay informed about how approvals like this one are unfolding, our latest news on Wegovy page tracks confirmed regulatory developments as they are announced. If you are thinking about what this approval means for you personally, our Wegovy overview explains the full dosing pathway and how a private consultation works.

The oral Wegovy approval: what the tablet news actually means

The MHRA's 11 June 2026 approval of Wegovy tablets made the UK the first country in Europe to license an oral GLP-1 medicine for weight management. The active ingredient is the same semaglutide, co-formulated with an absorption enhancer called SNAC so it can survive the digestive tract. The schedule runs from 1.5 mg daily up through 4 mg and 9 mg to a 25 mg maintenance dose, with at least a month at each step.

Taking it correctly matters. The tablet is taken first thing in the morning on an empty stomach, with no more than a small amount of plain water, and nothing else (no food, no coffee, no other oral medicines) for at least 30 minutes afterwards. There is no refrigeration requirement, which makes it meaningfully more practical for people who travel or who find the idea of self-injection difficult. Phase 3 trial data (OASIS 4, 307 adults, 64 weeks) reported average weight loss of around 13.6 % against placebo, rising to roughly 17 % among participants who adhered fully to the regimen. You can read more about how the tablet compares on the new Wegovy page.

What has not changed: this remains a prescription-only medicine. NHS availability would require a completed NICE appraisal, and none exists yet for the oral formulation. Private prescription is the current route. The cost of Wegovy treatment page covers what a private prescription typically involves.

The MASH liver-disease approval: what it means for weight-loss patients

On 3 July 2026 the MHRA granted conditional approval for semaglutide (Wegovy) to treat MASH (metabolic dysfunction-associated steatohepatitis) in adults with moderate-to-advanced fibrosis. MASH is a serious form of fatty liver disease linked to obesity and metabolic conditions.

This licence is distinct from the weight-management licence. It does not change how Wegovy is prescribed or accessed for weight loss, and it does not alter the eligibility criteria for people seeking treatment primarily for their weight. The significance for patients is contextual: for adults who carry excess weight alongside liver disease, semaglutide now has regulatory backing for both conditions, which may inform clinical conversations with specialists. The MHRA's announcement is available on GOV.UK and provides the full technical detail for those who want it.

num does not prescribe Wegovy for the liver indication, our prescribers assess for weight management. If liver disease is part of your health picture, it forms part of the clinical conversation during your consultation. Details of how that process works are on the about us page.

What stays the same, and how to decide your next step

Amid the activity, the core framework has not shifted. Wegovy (injection) remains a weekly subcutaneous injection, prescription-only, recommended by NICE (TA875) within specialist weight management services for up to two years. The BMI thresholds on the NHS are 35 or above with a weight-related condition, with lower thresholds applying for some ethnic backgrounds under UK guidance. Waiting lists through NHS specialist services remain long in most areas.

Private treatment through a regulated online pharmacy is the alternative for people who do not meet current NHS criteria or do not want to wait. The safe-route check is the same regardless of which news cycle brought you here: verify that any online pharmacy holds a current GPhC registration before sharing any personal or medical information with it. Our GPhC registration number is 9012878, verifiable directly on the GPhC register.

The broader picture of semaglutide's development (including what is still in trial stages) is covered on the semaglutide news page. For the latest updates as they are confirmed by UK regulators, you can follow semaglutide news today on our dedicated page, which we keep current as announcements land. If you are ready to find out whether treatment is clinically appropriate for you, the place to start is a free consultation with our prescribers.

Check your eligibility with a free consultation.